

## **Worcester Research and Publications**

Supplementary Material: Metabolic activity of CYP2C19 and CYP2D6 on antidepressant response from 13 clinical studies using genotype imputation: a meta-analysis

Item Type	Supplementary Material
UoW Affiliated Authors	Jones, Lisa
Full Citation	Li, D., Pain, O., Fabbri, C., Wong, W., Lo, C., Ripke, S., Cattaneo, A., Souery, D., Dernovsek, M., Henigsberg, N., Hauser, A., Lewis, G., Mors, O., Perroud, N., Rietschel, M., Uher, R., Maier, W., Baune, B., Biernacka, J., Bondolfi, G., Domschke, K., Kato, M., Liu, Y., Serretti, A., Tsai, S., Weinshilboum, R., Major Depressive Disorder Working Group, Psychiatric Genomics Consorti- um and Jones, Lisa (2024) Metabolic activity of CYP2C19 and CYP2D6 on anti- depressant response from 13 clinical studies using genotype imputation: a me- ta-analysis. Translational Psychiatry, 14 (296). pp. 1-8. ISSN 2158-3188
DOI/ISBN	https://doi.org/10.1038/s41398-024-02981-1
Journal/ Publisher	Translational Psychiatry Springer Nature Publishing
Rights/ Publisher Set Statement	Supplementary material is included under the same Creative Commons/Open Access licence as the rest of the article unless explicitly stated on the article webpage, as long as a clear acknowledgement to the original article is made and indicates any changes made (confirmed via email by Permissions Executive from SpringerNature 20/02/25)
	This version of the supplementary tables has been converted from the original word doc format to pdf.
	Copyright © 2024, The Author(s), Open Access Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Item License	CC BY 4.0
Link to item	https://www.nature.com/articles/s41398-024-02981-1

# Metabolic activity of CYP2C19 and CYP2D6 on antidepressant response from 13 clinical studies using genotype imputation: a meta-analysis

### Li D, Pain O, Fabbri C et al.

## Supplementary Materials

Supplementary Author List	
European Group for the Study of Resistant Depression (GSRD) Consortium	2
Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium	3
Supplementary Figures	
Supplementary Figure 1. Distribution of CYP2C19 and CYP2D6 antidepressants in each cohort	13
Supplementary Figure 2. Frequency of CYP2C19 and CYP2D6 star alleles	14
Supplementary Figure 3. Meta-analyses of CYP2C19 poor, intermediate, and ultrarapid metabolizers all samples	
Supplementary Figure 4. Meta-analyses of CYP2C19 poor, intermediate, and ultrarapid metabolizers CYP2C19 antidepressant group.	
Supplementary Figure 5. Association of metabolizer status with antidepressant outcomes in drugs not primarily metabolized by CYP2C19	
Supplementary Figure 6. Distribution of activity score in each cohort	18
Supplementary Tables	
Supplementary Table 1. Characteristics of 13 clinical studies	19
Supplementary Table 2. Star alleles in CYP2C19 and CYP2D6	20
Supplementary Table 3. Concordance rate and misclassification of CYP2C19 and CYP2D6 metabolic phenotypes between imputed genotype and Roche AmpliChip CYP450 microarray/TaqMan SNP genotyping in GENDEP	
Supplementary Table 4. CYP2C19 and CYP2D6 antidepressants	22
Supplementary Table 5. Remission and percentage improvement in CYP2C19 and CYP2D6 antidepressant groups	23
Supplementary Table 6. Meta-analyses of activity score with antidepressant outcomes	24
Supplementary Table 7. Meta-analyses of metabolic phenotypes for percentage improvement adjusting baseline severity of depression	_
Supplementary Table 8. Meta-analyses of CYP2C19 metabolic effect in citalopram and escitalopram.	26

#### **Supplementary Author List**

European Group for the Study of Resistant Depression (GSRD) Consortium

Siegfried Kasper, <sup>1</sup> Joseph Zohar, <sup>2</sup> Daniel Souery, <sup>3</sup> Stuart Montgomery, <sup>4</sup> Diego Albani, <sup>5</sup> Gianluigi Forloni, <sup>5</sup> Panagiotis Ferentinos, <sup>6</sup> Dan Rujescu, <sup>7</sup> Julien Mendlewicz. <sup>8</sup>

<sup>&</sup>lt;sup>1</sup>Department of Psychiatry and Psychotherapy, Medical University Vienna, Austria;

<sup>&</sup>lt;sup>2</sup>Department of Psychiatry, Sheba Medical Center, Tel Hashomer, and Sackler School of Medicine, Tel Aviv University, Israel;

<sup>&</sup>lt;sup>3</sup>Laboratoire de Psychologie Médicale, Université Libre de Bruxelles and Psy Pluriel, Centre Européen de Psychologie Médicale, Brussels;

<sup>&</sup>lt;sup>4</sup>Imperial College School of Medicine, London, UK;

<sup>&</sup>lt;sup>5</sup>Laboratory of Biology of Neurodegenerative Disorders, Neuroscience Department, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy;

<sup>&</sup>lt;sup>6</sup>Department of Psychiatry, Athens University Medical School, Athens, Greece;

<sup>&</sup>lt;sup>7</sup>University Clinic for Psychiatry, Psychotherapy and Psychosomatic, Martin-Luther-University Halle-Wittenberg, Germany;

<sup>&</sup>lt;sup>8</sup>Université Libre de Bruxelles.

#### Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium

Mark J Adams\* 1
Fabian Streit\* 2, 3, 4
Xiangrui Meng\* 5
Swapnil Awasthi\* 6
Brett N Adey 7
Karmel W Choi 8, 9
V Kartik Chundru 10, 11
Jonathan RI Coleman 7, 7, 12

Bart Ferwerda 13
Jerome C Foo 2, 14, 15, 16
Zachary F Gerring 17
Olga Giannakopoulou 5
Priya Gupta 18, 19
Alisha S M Hall 2, 20
Arvid Harder 21
David M Howard 7
Christopher Hübel 7, 22, 23

Alex S F Kwong 1, 24 Daniel F Levey 19, 25 Brittany L Mitchell 17 Guiyan Ni 26 Vanessa K Ota 27 Oliver Pain 28 Gita A Pathak 29, 30

Eva C Schulte 31, 32, 33, 34

Xueyi Shen 1 Jackson G Thorp 17 Alicia Walker 26 Shuyang Yao 21 Jian Zeng 26

Johan Zvrskovec 7, 12 Dag Aarsland 35 Ky'Era V Actkins 36 Mazda Adli 6, 37 Esben Agerbo 23, 38, 39 Mareike Aichholzer 40 Allison Aiello 41 Tracy M Air 42

Thomas D Als 39, 43, 44 Evelyn Andersson 45 Till F M Andlauer 46, 47

Volker Arolt 48
Helga Ask 49, 50
Sunita Badola 51
Clive Ballard 52
Karina Banasik 53
Nicholas J Bass 5
Aartjan T F Beekman 54
Sintia Belangero 27
Tim B Bigdeli 55

Elisabeth B Binder 46, 56 Ottar Bjerkeset 57, 58 Gyda Bjornsdottir 59 Julia Boberg 45 Sigrid Børte 60, 61, 62 Emma Bränn 63 Alice Braun 64
Thorsten Brodersen 65
Tanja M Brückl 66
Søren Brunak 53
Mie T Bruun 67
Margit Burmeister 68
Pichit Buspavanich 69, 70
Jonas Bybjerg-Grauholm 71, 72

Enda M Byrne 73
Jianwen Cai 74
Archie Campbell 75, 76
Megan L Campbell 77
Adrian I Campos 78
Enrique Castelao 79
Jorge Cervilla 80, 81
Boris Chaumette 82
Chia-Yen Chen 83
Hsi-Chung Chen 84
Zhengming Chen 85
Sven Cichon 86, 87, 88, 89

Anne Corbett 52

Elizabeth C Corfield 49, 91 Baptiste Couvy-Duchesne 92

Lucía Colodro-Conde 17, 90

Nick Craddock 93 Udo Dannlowski 48 Gail Davies 94 EJC de Geus 95 Ian J Deary 94

Franziska Degenhardt 87, 96 Abbas Dehghan 97, 98 J Raymond DePaulo 99 Michael Deuschle 100 Maria Didriksen 101 Khoa Manh Dinh 102 Nese Direk 103

Srdjan Djurovic 104, 105 Anna R Docherty 106, 107, 108 Katharina Domschke 109

Joseph Dowsett 101

Ole Kristian Drange 57, 110, 111, 112

Erin C Dunn 9, 113 William Eaton 114 Gudmundur Einarsson 59

Thalia C Eley 7

Samar S M Elsheikh 115 Jan Engelmann 116

Michael E Benros 72, 117, 118 Christian Erikstrup 102 Valentina Escott-Price 93 Chiara Fabbri 7, 119

Yu Fang 68 Sarah Finer 120 Josef Frank 2 Robert C Free 121 Linda Gallo 122 He Gao 123 Michael Gill 124 Maria Gilles 100 Fernando S Goes 99 Scott Douglas Gordon 17 Jakob Grove 39, 43, 44, 125 Daniel F Gudbjartsson 59, 126

Tim Hahn 48 Lynsey S Hall 93

Blanca Gutierrez 80, 81

Thomas F Hansen 53, 72, 127 Magnus Haraldsson 128 Catherina A Hartman 129 Alexandra Havdahl 49 Caroline Hayward 130

Stefanie Heilmann-Heimbach 87

Stefan Herms 86, 87 Ian B Hickie 131 Henrik Hjalgrim 132 Jens Hjerling-Leffler 133 Per Hoffmann 86, 87 Georg Homuth 134 Carsten Horn 135 Jouke-Jan Hottenga 95 David M Hougaard 71, 72

liris Hovatta 136 Qin Qin Huang 10 Donald Hucks 36 Floris Huider 95 Karen A Hunt 137 Nicholas S Ialongo 114 Marcus Ising 138 Erkki Isometsä 139 Rick Jansen 54 Yunxuan Jiang 140 Ian Jones 93 Lisa A Jones 141 Lina Jonsson 142

Masahiro Kanai 143, 144, 145

Robert Karlsson 21 Siegfried Kasper 146 Kenneth S Kendler 147 Ronald C Kessler 148

Stefan Kloiber 115, 138, 149, 150

James A Knowles 151 Nastassja Koen 77 Julia Kraft 64

Henry R Kranzler 152, 153

Kristi Krebs 154

Theodora Kunovac Kallak 155 Zoltán Kutalik 156, 157, 158

Elisa Lahtela 159
Marilyn Lake 160
Margit Hørup Larsen 101
Eric J Lenze 161
Melissa Lewins 1

Glyn Lewis 5 Liming Li 162, 163 Bochao Danae Lin 164 Kuang Lin 85

Kuang Lin 85 Penelope A Lind 17 Yu-Li Liu 165 Donald J MacIntyre 1

Dean F MacKinnon 99 Brion S Maher 114 Wolfgang Maier 166 Victoria S Marshe 115, 167 Gabriela A Martinez-levy 168 Koichi Matsuda 169, 170

Hamdi Mbarek 95 Peter McGuffin 7 Sarah E Medland 17 Susanne Meinert 48, 171 Christina Mikkelsen 101, 172 Susan Mikkelsen 102

Yuri Milaneschi 54 Iona Y Millwood 85 Esther Molina 81, 173 Francis M Mondimore 99 Preben Bo Mortensen 23, 38, 39 Benoit H Mulsant 115, 149 Joonas Naamanka 136 Jake M Najman 174

Matthias Nauck 175, 176 Igor Nenadić 177 Kasper R Nielsen 178 Ilja M Nolte 179

Merete Nordentoft 72, 117, 118

Markus M Nöthen 87

Mette Nyegaard 39, 180, 181, 182

Mette Nyegaard 39, 180, 181, Michael C O'Donovan 93 Asmundur Oddsson 59 Adrielle M Oliveira 183 Catherine M Olsen 184, 185 Hogni Oskarsson 186 Sisse Rye Ostrowski 101, 187

Michael J Owen 93
Richard Packer 188
Teemu Palviainen 159
Pedro M Pan 183
Carlos N Pato 189
Michele T Pato 189
Nancy L Pedersen 21
Ole Birger Pedersen 190
Wouter J Peyrot 54
James B Potash 99

Martin Preisig 79 Michael H Preuss 191, 192 Jorge A Quiroz 193 Miguel E Renteria 194 Charles F Reynolds III 195

John P Rice 161

Saori Sakaue 143, 144, 196 Marcos L Santoro 197 Robert A Schoevers 198, 199 Andrew Schork 39, 200, 201 Thomas G Schulze 2, 32, 99, 202,

203, 204

Tabea S Send 100 Jianxin Shi 205

Engilbert Sigurdsson 128

Kritika Singh 36

Grant C B Sinnamon 206

Lea Sirignano 2

Olav B Smeland 207, 208 Daniel J Smith 209 Tamar Sofer 210 Erik Sørensen 101

Sundararajan Srinivasan 211 Hreinn Stefansson 59 Kari Stefansson 59, 212

Peter Straub 36
Mei-Hsin Su 213
André Tadic 116, 214
Henning Teismann 215
Alexander Teumer 216
Anita Thapar 93, 217
Pippa A Thomson 76
Lise Wegner Thørner 101
Apostolia Topaloudi 218
Shih-Jen Tsai 219

Ioanna Tzoulaki 97, 98, 220

George Uhl 221

André G Uitterlinden 222 Henrik Ullum 101, 223, 224 Daniel Umbricht 225 Robert J Ursano 226 Sandra Van der Auwera 227 Albert M van Hemert 228

Albert M van Hemert 228 Abirami Veluchamy 211 Alexander Viktorin 21 Henry Völzke 216 G Bragi Walters 59 Xiaotong Wang 229 Agaz Wani 230

Myrna M Weissman 231, 232 Jürgen Wellmann 215 David C Whiteman 184 Derek Wildman 230 Gonneke Willemsen 95 Alexander T Williams 188 Bendik S Winsvold 61, 62, 233

Stephanie H Witt 2 Ying Xiong 21 Lea Zillich 2

John-Anker Zwart 60, 61, 62 23andMe Research Team 140 China Kadoorie Biobank Collaborative Group 234

Estonian Biobank Research Team

154

Genes & Health Research Team 235

HUNT All-In Psychiatry 236 The BioBank Japan Project 237 VA Million Veteran Program 238 Ole A Andreassen 207, 208, 239 Bernhard T Baune 240, 241, 242

Klaus Berger 215

Dorret I Boomsma 95, 243 Anders D Børglum 39, 43, 44

Gerome Breen 7, 12 Na Cai 244, 245, 246 Hilary Coon 107 William E Copeland 247 Byron Creese 52

Carlos S Cruz-Fuentes 248 Darina Czamara 66

Lea K Davis 36 Eske M Derks 17 Enrico Domenici 249 Paul Elliott 97, 98, 220, 250 Andreas J Forstner 87, 89, 251

Micha Gawlik 252

Joel Gelernter 19, 29, 253 Hans J Grabe 227 Steven P Hamilton 254 Kristian Hveem 255, 256, 257 Catherine John 188, 258 Jaakko Kaprio 159 Tilo Kircher 177 Marie-Odile Krebs 259 Po-Hsiu Kuo 84, 260

Mikael Landén 21, 142 Kelli Lehto 154

Douglas F Levinson 261 Qingqin S Li 262 Klaus Lieb 116

Ruth J F Loos 191, 263, 264, 265,

266 Yi Lu 21

Susanne Lucae 138
Jurjen J Luykx 164, 267
Hermine HM Maes 213, 268
Patrik K Magnusson 21
Hilary C Martin 10
Nicholas G Martin 17
Andrew McQuillin 5

Christel M Middeldorp 73, 269

Lili Milani 154 Ole Mors 39, 270

Daniel J Müller 115, 149, 150, 271 Bertram Müller-Myhsok 46, 272, 273 Yukinori Okada 143, 274, 275

Albertine J Oldehinkel 129 Sara A Paciga 276

Colin NA Palmer 211 Peristera Paschou 218 Brenda WJH Penninx 54 Roy H Perlis 8, 9, 277 Roseann E Peterson 55 Giorgio Pistis 79 Renato Polimanti 29, 30 David J Porteous 76 Danielle Posthuma 278, 279 Jill A Rabinowitz 189 Ted Reichborn-Kjennerud 49 Andreas Reif 40 Frances Rice 93, 217 Roland Ricken 6 Marcella Rietschel 2 Margarita Rivera 81, 280 Christian Rück 281 Giovanni A Salum 282 Catherine Schaefer 283

\* shared first and last authors V. 2024-04-26 15:00

Srijan Sen 68, 284 Alessandro Serretti 285 Alkistis Skalkidou 155 Jordan W Smoller 8, 286, 287 Dan J Stein 77 Frederike Stein 288 Murray B Stein 289, 290, 291, 292 Patrick F Sullivan 21 Martin Tesli 293 Thorgeir E Thorgeirsson 59 Henning Tiemeier 294, 295 Nicholas J Timpson 24, 296 Monica Uddin 230

Rudolf Uher 297

Karin JH Verweii 298 Robin G Walters 85 Sylvia Wassertheil-Smoller 299 Jens R Wendland 51 Thomas Werge 72, 200, 223, 300, Aeilko H Zwinderman 13 Karoline Kuchenbaecker\* 5, 85 Naomi R Wray\* 26, 229, 302 Stephan Ripke\* 6, 287 Cathryn M Lewis\* 7, 303 Andrew M McIntosh\* 1, 304

David A van Heel 137

- 1, Division of Psychiatry, University of Edinburgh, Edinburgh, UK
- 2, Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, BW, DE
- 3, Hector Institute for Artificial Intelligence in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, BW, DE
- 4, Department for Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, BW, DE
- 5, Division of Psychiatry, University College London, London, UK
- 6, Department of Psychiatry and Psychotherapy, Charité Universitätsmedizin Berlin, Berlin, BE, DE
- 7, Social, Genetic and Developmental Psychiatry Centre, King's College London, London, UK
- 8, Department of Psychiatry, Massachusetts General Hospital, Boston, MA, US
- 9, Department of Psychiatry, Harvard Medical School, Boston, MA, US
- 10, Human Genetics, Wellcome Sanger Institute, Hinxton, UK
- 11, Department of Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter, Exeter, UK
- 12, NIHR Maudsley Biomedical Research Centre, King's College London, London, UK
- 13, Epidemiologie en Data Science (EDS), Amsterdam UMC, location University of Amsterdam, Amsterdam, NL
- 14, Institute for Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, BW, DE
- 15, Department of Psychiatry, College of Health Sciences, University of Alberta, Edmonton, AB, CA
- 16, Neuroscience and Mental Health Institute, University of Alberta, Edmonton, AB, CA
- 17, Mental Health and Neuroscience, QIMR Berghofer Medical Research Institute, Brisbane, QLD, AU
- 18, Psychiatry, Yale University, New Haven, CT, US
- 19, Psychiatry, Veterans Affairs Connecticut Healthcare System, West Haven, CT, US
- 20, Department of Clinical Medicine, Aarhus University, Aarhus, DK
- 21, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, SE
- 22, Department of Pediatric Neurology, Charité Universitätsmedizin Berlin, Berlin, BE, DE
- 23, National Centre for Register-based Research, Aarhus University, Aarhus, DK
- 24, MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK
- 25, Department of Psychiatry, Yale University, New Haven, CT, US
- 26, Institute for Molecular Bioscience, University of Queensland, Brisbane, QLD, AU
- 27, Morphology and Genetics, Universidade Federal de Sao Paulo, Sao Paulo, SP, BR
- 28, Maurice Wohl Clinical Neuroscience Institute, Department of Basic and Clinical Neuroscience, King's College London, London, UK
- 29, Department of Psychiatry, Yale University School of Medicine, New Haven, CT, US
- 30, Veterans Affairs Connecticut Healthcare System, West Haven, CT, US
- 31, Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, BY, DE
- 32, Institute of Psychiatric Phenomics and Genomics, University Hospital, LMU Munich, Munich, BY, DE
- 33, Department of Psychiatry and Psychotherapy, University Hospital Bonn, Medical Faculty, University of Bonn, Bonn, DE
- 34, Institute of Human Genetics, University Hospital Bonn, Medical Faculty, University of Bonn, Bonn, DE
- 35, Old Age Psychiatry, King's College London, London, UK
- 36, Department of Medicine, Division of Genetic Medicine, Vanderbilt University Medical Center, Nashville, TN, US
- 37, Department of Psychiatry and Psychotherapy, Fliedner Klinik Berlin, Berlin, BE, DE
- 38, Centre for Integrated Register-based Research, Aarhus University, Aarhus, DK
- 39, iPSYCH, The Lundbeck Foundation Initiative for Integrative Psychiatric Research, Aarhus, DK
- 40, Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, Goethe University Frankfurt University Hospital, Frankfurt am Main, DE
- 41, Department of Epidemiology, Columbia University Mailman School of Public Health, New York, NY, US
- 42, Discipline of Psychiatry, University of Adelaide, Adelaide, SA, AU
- 43, Department of Biomedicine and Centre for Integrative Sequencing, iSEQ, Aarhus University, Aarhus, DK
- 44, Center for Genomics and Personalized Medicine, Aarhus University, Aarhus, DK
- 45, Department of Clinical Neuroscience, Karolinska Institutet, SE
- 46, Department of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, Munich, BY, DE
- 47, Department of Neurology, Klinikum rechts der Isar, Technical University of Munich, Munich, BY, DE
- 48, Institute for Translational Psychiatry, University of Münster, Münster, NRW, DE
- 49, PsychGen Centre for Genetic Epidemiology and Mental Health, Norwegian Institute of Public Health, Oslo, NO
- 50, PROMENTA Research Center, Department of Psychology, University of Oslo, Oslo, NO
- 51, Research and Development, Takeda Pharmaceutical Company Limited, Cambridge, MA, US
- 52, Faculty of Health and Life Sciences, University of Exeter, Exeter, UK

- 53, Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DK
- 54, Department of Psychiatry, Amsterdam Public Health and Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, NL
- 55, Department of Psychiatry and Behavioral Sciences, Institute for Genomics in Health, State University of New York Downstate Health Sciences University, Brooklyn, NY, US
- 56, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, US
- 57, Department of Mental Health, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, TRD, NO
- 58, Faculty of Nursing and Health Sciences, NORD University, Levanger, NO
- 59, deCODE Genetics / Amgen, Reykjavik, IS
- 60, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, NO
- 61, K. G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, TRD, NO
- 62, Department of Research and Innovation, Division of Clinical Neuroscience, Oslo University Hospital, Oslo, NO
- 63, Institute of Environmental Medicine, Unit of Integrative Epidemiology, Karolinska Institutet, Stockholm, SE
- 64, Department of Psychiatry and Psychotherapy, Charité Universitätsmedizin Berlin, Berlin, DE
- 65, Department of Clinical Immunology, Roskilde University/Næstved Hospital, Roskilde, DK
- 66, Department Genes & Environment, Max Planck Institute of Psychiatry, Munich, DE
- 67, Department of Clinical Immunology, Odense University Hospital, Odense, DK
- 68, Michigan Neuroscience Institute, University of Michigan, Ann Arbor, MI, US
- 69, Department of Psychiatry and Psychotherapy, Gender Research in Medicine, Institute of Sexology and Sexual Medicine, Charité Universitätsmedizin Berlin, Berlin, BE, DE
- 70, Department of Psychiatry, Psychotherapy and Psychosomatics, Brandenburg Medical School Theodor Fontane, Neuruppin, BB, DE
- 71, Center for Neonatal Screening, Department for Congenital Disorders, Statens Serum Institut, Copenhagen, DK
- 72, iPSYCH, The Lundbeck Foundation Initiative for Integrative Psychiatric Research, Copenhagen, DK
- 73, Child Health Research Centre, University of Queensland, Brisbane, QLD, AU
- 74, Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, US
- 75, Centre for Medical Informatics, Usher Institute, University of Edinburgh, Edinburgh, UK
- 76, Centre for Genomic & Experimental Medicine, Institute for Genetics and Cancer, University of Edinburgh, Edinburgh, UK
- 77, SAMRC Unit on Risk & Resilience in Mental Disorders, Department of Psychiatry and Neuroscience Institute, University of Cape Town, Cape Town, SA
- 78, Statistical genetics, Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, AU
- 79, Department of Psychiatry, Lausanne University Hospital and University of Lausanne, Prilly, VD, CH
- 80, Department of Psychiatry, Faculty of Medicine and Institute of Neurosciences, Biomedical Research Centre (CIBM), University of Granada, Granada, ES
- 81, Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, ES
- 82, Université de Paris Cité, INSERM U1266, Institute of Psychiatry and Neuroscience of Paris, GHU Paris Psychiatry and Neuroscience, Paris, FR
- 83, Biogen, Cambridge, MA, US
- 84, Department of Psychiatry, National Taiwan University Hospital, TW
- 85, Nuffield Department of Population Health, University of Oxford, Oxford, UK
- 86, Human Genomics Research Group, Department of Biomedicine, University of Basel, Basel, CH
- 87, Institute of Human Genetics, University of Bonn, School of Medicine & University Hospital Bonn, Bonn, DE
- 88, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, CH
- 89, Institute of Neuroscience and Medicine (INM-1), Research Center Juelich, Juelich, DE
- 90, School of Psychology, University of Queensland, Brisbane, QLD, AU
- 91, Nic Waals Institute, Lovisenberg Diakonale Hospital, Oslo, NO
- 92, Centre for Advanced Imaging, University of Queensland, Saint Lucia, QLD, AU
- 93, Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK
- 94, The Lothian Birth Cohorts, University of Edinburgh, Edinburgh, UK
- 95, Department of Biological Psychology & Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam, Amsterdam, NL
- 96, Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital Essen, University of Duisburg-Essen, Duisburg, DE
- 97, MRC Centre for Environment and Health, School of Public Health, Imperial College London, London, UK

- 98, Imperial College Dementia Research Institute, Imperial College London, London, UK
- 99, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, US
- 100, Department of Psychiatry and Psychotherapy, Research Group Stress Related Disorders, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, BW, DE
- 101, Department of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, CPH, DK
- 102, Department of Clinical Immunology, Aarhus University Hospital, Aarhus, DK
- 103, Department of Psychiatry, Istanbul University, Istanbul, TR
- 104, Department of Medical Genetics, Oslo University Hospital, Oslo, OSL, NO
- 105, NORMENT, Department of Clinical Science, University of Bergen, Bergen, NO
- 106, Virginia Institute for Psychiatric & Behavioral Genetics, Virginia Commonwealth University, Richmond, VA, US
- 107, Psychiatry Department / Huntsman Mental Health Institute, University of Utah School of Medicine, Salt Lake City, UT, US
- 108, Center for Genomic Research, University of Utah School of Medicine, Salt Lake City, UT, US
- 109, Department of Psychiatry and Psychotherapy, Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, DE
- 110, Division of Mental Health Care, St. Olavs Hospital, Trondheim University Hospital, Trondheim, TRD, NO
- 111, Department of Psychiatry, Sørlandet Hospital, Kristiansand, AG, NO
- 112, University of Oslo, NORMENT Centre, Institute of Clinical Medicine, Oslo, OSL, NO
- 113, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, US
- 114, Department of Mental Health, Johns Hopkins, Baltimore, MD, US
- 115. Centre for Addiction and Mental Health. Toronto. ON. CA
- 116, Department of Psychiatry and Psychotherapy, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, DE
- 117, Mental Health Center Copenhagen, Mental Health Services Capital Region of Denmark, Copenhagen, DK
- 118, Faculty of Health Science, Department of Clinical Medicine, University of Copenhagen, Copenhagen, DK
- 119, Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, IT
- 120, Wolfson Institute of Population Health, Queen Mary University of London, London, UK
- 121, School of Computing and Mathematical Sciences, University of Leicester, Leicester, UK
- 122, Department of Psychology, San Diego San Diego State University, San Diego, CA, US
- 123, Department of Epidemiology and Biostatistics, Imperial College London, London, UK
- 124, Discipline of Psychiatry, School of Medicine, Trinity College Dublin, Dublin, IE
- 125, Bioinformatics Research Centre, Aarhus University, Aarhus, DK
- 126, School of Engineering, University of Iceland, Reykjavik, IS
- 127, Danish Headache Centre, Department of Neurology, Rigshospitalet, Glostrup, DK
- 128, Faculty of Medicine, Department of Psychiatry, University of Iceland, Reykjavik, IS
- 129, Department of Psychiatry, University of Groningen, University Medical Center Groningen, Groningen, NL
- 130, MRC Human Genetics Unit, Institute for Genetics and Cancer, University of Edinburgh, Edinburgh, UK
- 131, Brain and Mind Centre, University of Sydney, Sydney, NSW, AU
- 132, Department of Epidemiology Research, Statens Serum Institut, Copenhagen, DK
- 133, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, SE
- 134, Interfaculty Institute for Genetics and Functional Genomics, Department of Functional Genomics, University Medicine Greifswald, Greifswald, MV, DE
- 135, Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, CH
- 136, SleepWell Research Program and Department of Psychology and Logopedics, University of Helsinki, Helsinki, FI
- 137, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
- 138, Max Planck Institute of Psychiatry, Munich, BY, DE
- 139, Department of Psychiatry, University of Helsinki, Helsinki, FI
- 140, 23andMe Research Team, 23andMe, Inc., Sunnyvale, CA, US
- 141, Department of Psychological Medicine, University of Worcester, Worcester, UK
- 142, Institution of Neuroscience and Physiology, University of Gothenburg, Gothenburg, SE
- 143, Department of Statistical Genetics, Osaka University Graduate School of Medicine, Suita, JP
- 144, Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, US
- 145, Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, MA, US
- 146, Center for Brain Research, Department of Molecular Neuroscience, Medical University of Vienna, Vienna, AT
- 147, Department of Psychiatry, Virginia Commonwealth University, Richmond, VA, US
- 148, Health Care Policy, Harvard Medical School, Boston, MA, US

- 149, Department of Psychiatry, University of Toronto, Toronto, ON, CA
- 150, Department of Pharmacology & Toxicology, University of Toronto, Toronto, ON, CA
- 151, Department of Genetics, Rutgers University, Piscataway, NJ, US
- 152, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, US
- 153, Mental Illness Research, Education and Clinical Center, Crescenz VA Medical Center, Philadelphia, PA, US
- 154, Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, EE
- 155, Department of Women's and Children's Health, Uppsala University, Uppsala, SE
- 156, Department of Epidemiology and Health Systems, Center for Primary Care and Public Health, Lausanne, VD, CH
- 157, Department of Computational Biology, University of Lausanne, Lausanne, VD, CH
- 158, Swiss Institute of Bioinformatics, Lausanne, VD, CH
- 159, Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, FI
- 160, SAMRC Unit on Risk & Resilience in Mental Disorders, Department of Psychiatry and Neuroscience Institute, University of Cape Town, Cape Town, SA
- 161, Department of Psychiatry, Washington University School of Medicine in St. Louis, St. Louis, MO, US
- 162, Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, CN
- 163, Peking University Center for Public Health and Epidemic Preparedness & Response, Peking University, Beijing, CN
- 164, Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Centre, Maastricht, NL
- 165, Center for Neuropsychiatric Research, National Health Research Institutes, TW
- 166, Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, DE
- 167, Center for Translational and Computational Neuroimmunology, Columbia University Medical Center, New York, NY, US
- 168, Psychiatric Genetics, INPRFM, Mexico City, CDMX, GB
- 169, Laboratory of Genome Technology, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, JP
- 170, Laboratory of Clinical Genome Sequencing, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, JP
- 171, Institute for Translational Neuroscience, University of Münster, Münster, NRW, DE
- 172, Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DK
- 173, Department of Nursing, Faculty of Health Sciences and Institute of Neurosciences, Biomedical Research Centre (CIBM), University of Granada, Granada, ES
- 174, School of Public Health, University of Queensland, Brisbane, QLD, AU
- 175, Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, MV, DE
- 176, DZHK (German Centre for Cardiovascular Research), Partner Site Greifswald, Greifswald, MV, DE
- 177, Department of Psychiatry, University of Marburg, Marburg, DE
- 178, Department of Clinical Immunology, Aalborg University Hospital, Aalborg, DK
- 179, Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, NL
- 180, Centre for Integrative Sequencing, iSEQ, Aarhus University, Aarhus, DK
- 181, Department of Biomedicine-Human Genetics, Aarhus University, Aarhus, DK
- 182, Department of Health, Science and Technology, Aalborg University, Aalborg, DK
- 183, Department of Psychiatry, Universidade Federal de Sao Paulo, Sao Paulo, SP, BR
- 184, Population Health, QIMR Berghofer Medical Research Institute, Brisbane, QLD, AU
- 185, The Fraser Institute, Faculty of Medicine, University of Queensland, Brisbane, QLD, AU
- 186, Humus, Reykjavik, IS
- 187, Department of Clinical Medicine, University of Copenhagen, Copenhagen, CPH, DK
- 188, Department of Population Health Sciences, University of Leicester, Leicester, UK
- 189, Department of Psychiatry, Rutgers University, Piscataway, NJ, US
- 190, Department of Clinical Immunology, Zealand University Hospital, Køge, DK
- 191, Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, US
- $192, Department of Environmental \, Medicine \, and \, Public \, Health, \, Icahn \, School \, of \, Medicine \, at \, Mount \, Sinai, \, New \, York, \, NY, \, US \, And \, Contract \, Contra$
- 193, NMD Pharma, Lexington, MA, US
- 194, Mental Health and Neuroscience Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD, AU
- 195, Psychiatry, University of Pittsburgh Medical Centre, Pittsburgh, PA, US
- 196, Divisions of Genetics and Rheumatology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, US
- 197, Department of Biochemistry, Universidade Federal de Sao Paulo, Sao Paulo, SP, BR
- 198, Department of Psychiatry, University Medical Center Groningen, Groningen, NL


- 199, Research School of Behavioural and Cognitive Neurosciences (BCN), University of Groningen, Groningen, NL
- 200, Institute of Biological Psychiatry, Mental Health Center Sct. Hans, Mental Health Services Capital Region of Denmark, Copenhagen, DK
- 201, Neurogenomics Division, The Translational Genomics Research Institute (TGEN), Phoenix, AZ, US
- 202, Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Goettingen, NI, DE
- 203, Human Genetics Branch, NIMH Division of Intramural Research Programs, Bethesda, MD, US
- 204, Department of Psychiatry and Behavioral Sciences, SUNY Upstate Medical University, Syracuse, NY, USA
- 205, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, US
- 206, School of Medicine and Dentistry, James Cook University, Townsville, QLD, AU
- 207, NORMENT, Institute of Clinical Medicine, University of Oslo, Oslo, OSL, NO
- 208, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, OSL, NO
- 209, Center for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
- 210, Beth Israel Deaconess Medica, Harvard Medical School, Boston, MA, US
- 211, Division of Population Health and Genomics, Ninewells Hospital and School of Medicine, University of Dundee, Dundee, UK
- 212, Faculty of Medicine, University of Iceland, Reykjavik, IS
- 213, Virginia Institute for Psychiatric and Behavioral Genetics, Virginia Commonwealth University, Richmond, VA, US
- 214, Department of Psychiatry, Psychotherapy and Psychosomatics, Dr. Fontheim Mentale Gesundheit, Liebenburg, DE
- 215, Institute of Epidemiology and Social Medicine, University of Münster, Münster, NRW, DE
- 216, Institute for Community Medicine, University Medicine Greifswald, Greifswald, MV, DE
- 217, Wolfson Centre for Young People's Mental Health, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK
- 218, Department of Biological Sciences, Purdue University, West Lafayette, IN, US
- 219, Institute of Brain Science & Division of Psychiatry, National Yang-Ming University, TW
- 220, Imperial College BHF Centre for Research Excellence, Imperial College London, London, UK
- 221, New Mexico VA Health Care System, Albequerque, NM, US
- 222, Department of Internal Medicine, Erasmus University Medical Center Rotterdam, Rotterdam, NL
- 223, Department of Clinical Medicine, University of Copenhagen, Copenhagen, DK
- 224, Management Section, Statens Serum Institut, Copenhagen, DK
- 225, Xperimed LLC, Basel, CH
- 226, Department of Psychiatry, Uniformed Services University of the Health Sciences, Bethesda, MD, US
- 227, Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald, MV, DE
- 228, Department of Psychiatry, Leiden University Medical Center, Leiden, NL
- 229, Department of Psychiatry, University of Oxford, Oxford, UK
- 230, Genomics Program, University of South Florida College of Public Health, Tampa, FL, US
- 231, Division of Epidemiology, New York State Psychiatric Institute, New York, NY, US
- 232, Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, US
- 233, Department of Neurology, Oslo University Hospital, Oslo, NO
- 234, China Kadoorie Biobank Collaborative Group
- 235, Genes & Health Research Team
- 236, HUNT All-In Psychiatry
- 237, The BioBank Japan Project
- 238, VA Million Veteran Program
- 239, KG Jebsen Centre for Neurodevelopmental Research, University of Oslo, Oslo, OSL, NO
- 240, Department of Psychiatry, University of Münster, Münster, NRW, DE
- 241, Department of Psychiatry, University of Melbourne, Melbourne, VIC, AU
- 242, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, VIC, AU
- 243, Department of Complex Trait Genetics, CNCR, Vrije Universiteit Amsterdam, Amsterdam, NL
- 244, Helmholtz Pioneer Campus, Helmholtz Zentrum München, Neuherberg, DE
- 245, Computational Health Centre, Helmholtz Zentrum München, Neuherberg, DE
- 246, School of Medicine, Technical University of Munich, Munich, BY, DE
- 247, Department of Psychiatry, University of Vermont, Burlington, VT, US
- 248, Psychiatric Genetics, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz (INPRFM), Mexico City, CDMX, MX
- 249, Department of Cellular, Computational and Integrative Biology, Università degli Studi di Trento, Trento, IT
- 250, Imperial College Biomedical Research Centre, Imperial College London, London, UK
- 251, Center for Human Genetics, University of Marburg, Marburg, DE
- 252, Department of Psychiatry, Psychosomatics and Psychotherapy, Julius-Maximilians-Universität Würzburg, Würzburg, DE

- 253, Department of Genetics, Department of Neuroscience, Yale University School of Medicine, New Haven, CT, US
- 254, Psychiatry, Kaiser Permanente Northern California, San Francisco, CA, US
- 255, K. G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, NO
- 256, HUNT Research Center, Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, NO
- 257, Department of Research, Innovation and Education, St. Olavs Hospital, Trondheim University Hospital, Trondheim, NO
- 258, NIHR Leicester Biomedical Research Centre, Glenfield Hospital, Leicester, UK
- 259, Pathophysiology of Psychiatric Diseases, INSERM, Univ Paris Cité, GHU Paris, Paris, FR
- 260, Institute of Epidemiology and Preventive Medicine & Department of Public Health, National Taiwan University, TW
- 261, Department of Psychiatry & Behavioral Sciences, Stanford University, Stanford, CA, US
- 262, Neuroscience Therapeutic Area, Janssen Research and Development, LLC, Titusville, NJ, US
- 263, Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Science, University of Copenhagen, Copenhagen, DK
- 264, Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, NY, US
- 265, Department of Environmental Medicine and Public Health, Icahn School of Medicine at Mount Sinai, New York, NY, US
- 266, MRC Metabolic Diseases Unit, University of Cambridge Metabolic Research Laboratories, Wellcome-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK
- 267, Second Opinion Outpatient Clinic, GGNet Mental Health, Warnsveld, NL
- 268, Department of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA, US
- 269, Child and Youth Mental Health Service, Children's Health Queensland Hospital and Health Service, Brisbane, QLD, AU
- 270, Psychosis Research Unit, Aarhus University Hospital-Psychiatry, Aarhus, DK
- 271, Department of Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Würzburg, Würzburg, DE
- 272, Munich Cluster for Systems Neurology (SyNergy), Munich, BY, DE
- 273, University of Liverpool, Liverpool, UK
- 274, Department of Genome Informatics, Graduate School of Medicine, The University of Tokyo, Tokyo, JP
- 275, Laboratory for Systems Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama, JP
- 276, Human Genetics and Computational Biomedicine, Pfizer Global Research and Development, Groton, CT, US
- 277, Centre for Quantitative Health, Massachusetts General Hospital, Boston, MA, US
- 278, Child and Adolescent Psychiatry, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, NL
- 279, Complex Trait Genetics, Vrije Universiteit Amsterdam, Amsterdam, NL
- 280, Department of Biochemistry and Molecular Biology II, Faculty of Pharmacy and Institute of Neurosciences, Biomedical Research Centre (CIBM), University of Granada, Granada, ES
- 281, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, SE
- 282, Psychiatry, Universidade Federal do Rio Grande do Sul, Porto Alegre, BR
- 283, Division of Research, Kaiser Permanente Northern California, Oakland, CA, US
- 284, Eisenberg Family Depression Center, University of Michigan, Ann Arbor, MI, US
- 285, Department of Medicine and Surgery, Kore University of Enna, Enna, IT
- 286, Psychiatric and Neurodevelopmental Genetics Unit, Massachusetts General Hospital, Boston, MA, US
- 287, Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, US
- 288, Department of Psychiatry and Psychotherapy, University of Marburg, Marburg, HE, DE
- 289, Psychiatry and Public Health, University of California, San Diego, La Jolla, CA, US
- 290, Psychiatry, Veterans Affairs San Diego Healthcare System, San Diego, CA, US
- 291, Psychiatry, UCSD School of Medicine, La Jolla, CA, US
- 292, Public Health, UCSD School of Public Health, La Jolla, CA, US
- 293, Department of Mental Health and Suicide, Norwegian Institute of Public Health, Oslo, NO
- 294, Child and Adolescent Psychiatry, Erasmus University Medical Center Rotterdam, Rotterdam, NL
- 295, Social and Behavioral Science, Harvard T.H. Chan School of Public Health, Boston, MA, US
- 296, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
- 297, Psychiatry, Dalhousie University, Halifax, NS, CA
- 298, Psychiatry, Amsterdam UMC, location University of Amsterdam, Amsterdam, NL
- 299, Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, US
- 300, Institute of Biological Psychiatry, Mental Health Center Sct. Hans, Copenhagen University Hospital, Mental Health Services, Copenhagen, DK
- 301, GLOBE Institute, Lundbeck Foundation Centre for Geogenetics, University of Copenhagen, Copenhagen, DK
- 302, Queensland Brain Institute, University of Queensland, Brisbane, QLD, AU


303, Department of Medical & Molecular Genetics, King's College London, London, UK 304, Institute for Genomics and Cancer, University of Edinburgh, Edinburgh, UK

#### **Supplementary Figures**

Supplementary Figure 1. Distribution of CYP2C19 and CYP2D6 antidepressants in each cohort




#### Supplementary Figure 2. Frequency of CYP2C19 and CYP2D6 star alleles




## Supplementary Figure 3. Meta-analyses of CYP2C19 poor, intermediate, and ultrarapid metabolizers in all samples

#### CYP2C19 poor metabolizers



#### CYP2C19 intermediate metabolizers




#### CYP2C19 rapid and ultrarapid metabolizers

	•		•						Standardised Mean			
Study	Coefficient	SE Odds Ratio	OR	95%-CI	Weight	Study	Coefficient	SE	Difference	SMD	95%-CI	Weight
Ancestry = Europea	an	1				Ancestry = Europe			1			
gods	-0.88 0.79	151	0.41	[0.09; 1.97]	0.9%	mayo	-0.16		<del>-+</del>		[-0.56; 0.25]	2.5%
mayo	-0.24 0.44	67	0.79	[0.33; 1.89]	2.7%	pgrn	-0.09		-+	-0.09	[-0.33; 0.14]	7.4%
gendep	-0.23 0.19	167	0.79	[0.54; 1.17]	13.8%	gendep	-0.09		*		[-0.26; 0.07]	15.0%
stard	-0.18 0.14	05	0.84	[0.63; 1.10]	26.7%	gods		0.2848	<del></del>		[-0.55; 0.57]	1.3%
pfz	-0.14 0.29	38 -	0.87	[0.49; 1.55]	6.2%	gsrd		0.0700	+		[-0.12; 0.16]	21.7%
gsrd	-0.01 0.19	167		[0.67; 1.46]	13.8%	pfz		0.1335	+		[-0.22; 0.30]	6.0%
pgrn	0.16 0.22	30 +-	1.18	[0.76; 1.82]	10.7%	genpod		0.1088	+		[-0.16; 0.27]	9.0%
dast	0.21 0.20	162	1.23	[0.82; 1.85]	12.5%	stard		0.0680	*		[-0.07; 0.20]	23.0%
genpod	0.34 0.23	143		[0.89; 2.22]	9.7%	dast		0.0973	+			11.2%
qsk	0.56 0.44	83		[0.73; 4.22]	2.7%	gsk		0.2147	<del></del>		[-0.29; 0.55]	2.3%
Random effects mo	del	<b>\$</b>		[0.85; 1.16]		Random effects m			Ŷ	0.01	[-0.05; 0.08]	99.4%
Heterogeneity: $I^2 = 9\%$ , $\tau^2 =$	0.0055, p = 0.36					Heterogeneity: $I^2 = 0\%$ , $\tau^2$	^ = 0, p = 0.89					
Ancestry = Asian						Ancestry = Asian						
japan	-0.54 1.36	:20	0.50	[0.04; 8.42]	0.3%	taipei	-0.69				[-2.11; 0.73]	0.2%
Japan	-0.54 1.50		0.50	[0.04, 0.42]	0.5 /6	japan	-0.07		<del></del>		[-1.25; 1.11]	0.3%
Random effects mo	del	1	0 99	[0.85; 1.14]	100.0%	miaoli		1.0063 -			[-1.96; 1.99]	0.1%
Heterogeneity: $I^2 = 1\%$ , $\tau^2 =$			0.55	[0.00, 1.14]	100.070	Random effects m				-0.26	[–1.09; 0.56]	0.6%
Residual heterogeneity: $I^2$ =		0.1 0.5 1 2	10			Heterogeneity: $I^2 = 0\%$ , $\tau^2$	$\hat{r} = 0, p = 0.77$		1			
Test for subgroup difference			10			D			1	0.01	0.05.0.001	100.00/
szzgroup amoronoc	A1	,				Random effects m			Y	J 0.01	[-0.05; 0.08]	100.0%
						Heterogeneity: $I^2 = 0\%$ , $\tau^i$ Residual heterogeneity: $I^i$		-2	_1 0 1	2		
						Test for subgroup differen			-1 0 1	2		
						rest for subgroup differen	ices: $\chi_1 = 0.43$ , $\alpha r = 1$ ( $p =$	0.51)				

SE: standard deviation, CI: confidence interval

GODS and PFZ were removed in the meta-analysis of poor metabolizer for remission outcome and



#### Supplementary Figure 4. Meta-analyses of CYP2C19 poor, intermediate, and ultrarapid metabolizers in CYP2C19 antidepressant group

95%-CI Weight

Standardised Mean

Difference


SMD

95%-CI Weight


Coefficient

#### CYP2C19 poor metabolizers Coefficient SE

Odds Ratio




#### CYP2C19 rapid and ultrarapid metabolizers




For the remission outcome, DAST, GENPOD, and JAPAN were removed in the meta-analysis of poor metabolizer and MIAOLI and TAIPEI were not reported in the meta-analysis of rapid+ultrarapid metabolizer due to insufficient sample size.

Supplementary Figure 5. Association of metabolizer status with antidepressant outcomes in drugs not primarily metabolized by CYP2C19



Group	Remission	OR (95% CI)	Percentage Improvement	SMD (95% CI)
CYP2D6				
PM		1.09 [0.77, 1.53]		-0.02 [-0.17, 0.13]
IM		1.06 [0.92, 1.22]		0.05 [-0.02, 0.11]

#### Supplementary Figure 6. Distribution of activity score in each cohort



#### **Supplementary Tables**

Supplementary Table 1. Characteristics of 13 clinical studies

Studies	Sample size (N = 5843)	Study design	Study weeks	Measures	Antidepressants	Age	Sex (Female)	Remission rate
European								
STARD	1163	Open label	12	QIDSC	Citalopram	43.33 (13.49)	675 (58.0%)	43.5%
GSRD	1152	Naturalistic Partially	≥4	MADRS	Various	52.23 (14.02)	758 (65.8%)	16.4%
GENDEP	783	randomized open label	12	MADRS	Escitalopram, nortriptyline	42.28 (11.59)	490 (62.6%)	37.2%
DAST	586	Naturalistic inpatient	6	HAMD-21	Various	49.47 (15.48)	335 (57.2%)	41.8%
PGRN	490	Open label	8	QIDSC	Citalopram, escitalopram	39.86 (13.64)	307 (62.7%)	40.8%
<b>GENPOD</b>	474	Open label	12	BDI	Citalopram, reboxetine	39.39 (12.50)	327 (69.0%)	35.7%
PFZ	309	RCT	6-8	HAMD-17	Sertraline, fluoxetine, paroxetine	43.17 (13.06)	208 (67.3%)	32.0%
MAYO	156	Open label	8	HAMD-17	Citalopram, escitalopram	40.03 (13.88)	96 (61.5%)	51.3%
GSK	132	RCT	8	HAMD-17	Escitalopram	36.36 (11.90)	72 (54.5%)	42.4%
GODS	71	Open label	8	MADRS	Paroxetine	37.32 (10.34)	37 (52.1%)	23.9%
East Asian								-
MIAOLI	233	Open label	8	HAMD-17	Escitalopram, paroxetine	41.36 (13.60)	192 (82.4%)	44.2%
TAIPEI	174	Open label	8	HAMD-17	Fluoxetine, citalopram	47.01 (15.13)	96 (55.2%)	25.9%
JAPAN	120	RCT	6	HAMD-17	Fluvoxamine, paroxetine	45.99 (15.25)	56 (46.7%)	65.0%

Mean with standard deviation for age and frequency with proportion for sex were displayed.

BDI, Beck Depression Inventory; HAMD-17, 17-item Hamilton Depression Rating Scale; HAMD-21, 21-item Hamilton Depression Rating Scale; MADRS, Montgomery Åsberg Depression Rating Scale; QIDSC, Quick Inventory of Depressive Symptomatology; RCT: randomized controlled trial.

Supplementary Table 2. Star alleles in CYP2C19 and CYP2D6

Star alleles	Defining variants	Function	Activity value
CYP2C19			
*1	Reference allele	Normal	1
*2	rs4244285	No	0
*3	rs4986893	No	0
*8	rs41291556	No	0
*11	rs58973490	Normal	1
*17	rs12248560	Increased	1.5
*35	rs12769205	No	0
CYP2D6		•	
*1	Reference allele	Normal	1
*2	rs16947, rs1135840	Normal	1
*3	rs35742686	No	0
*4	rs3892097	No	0
*6	rs5030655	No	0
*9	rs5030656	Decreased	0.5
*10	rs1135840, rs1065852	Decreased	0.25
*14	rs5030865, rs16947, rs1135840	Decreased	0.5
*17	rs28371706, rs16947, rs1135840	Decreased	0.5
*33	rs28371717	Normal	1
*34	rs16947	Normal	1
*35	rs769258	Normal	1
*39	rs1135840	Normal	1
*41	rs28371725, rs16947,	Decreased	0.5
	rs1135840		
*69	rs28371725 rs1065852	No	0
*114	rs5030865, rs1065852	No	0

Defining variants were based on the Clinical Pharmacogenetics Implementation Consortium (CPIC) allele definition table.

Supplementary Table 3. Concordance rate and misclassification of CYP2C19 and CYP2D6 metabolic phenotypes between imputed genotype and Roche AmpliChip CYP450 microarray/TaqMan SNP genotyping in GENDEP

	Roche Amp	Roche AmpliChip CYP450 microarray/TaqMan SNP genotyping						
		CYP2C19/CYP2D6						
Imputed genotype	Poor	Intermediate	Normal	Rapid+Ultrarapid				
CYP2C19								
Poor	88.2%	5.9%	5.9%	0				
Intermediate	0	96.1%	3.4%	0.5%				
Normal	0	1.4%	96.6%	0.7%				
Rapid+Ultrarapid	0	2.6%	0	97.0%				
CYP2D6								
Poor	88.2%	5.9%	2.9%	0				
Intermediate	6.9%	83.8%	6.2%	0				
Normal	1.5%	13.7%	76.7%	5.2%				

Supplementary Table 4. CYP2C19 and CYP2D6 antidepressants

	11	·
	Gene	Antidepressants
	CYP2C19	citalopram, escitalopram, sertraline, amitriptyline, clomipramine,
		doxepin, trimipramine
Ī	CYP2D6	paroxetine, nortriptyline, venlafaxine, fluvoxamine, amitriptyline,
		clomipramine, trimipramine, desipramine, doxepin

Supplementary Table 5. Remission and percentage improvement in CYP2C19 and CYP2D6

antidepressant groups

Metabolizers	N	Remission	Percentage Improvement	
CYP2C19 antidepressan	t group (1	N = 3390)		
Poor	92	42 (45.7%)	0.190 (1.040)	
Intermediate	907	353 (38.9%)	0.018 (0.975)	
Normal	1343	571 (42.5%)	0.007 (1.037)	
Rapid+Ultrarapid	1048	438 (41.8%)	0.039 (1.016)	
CYP2D6 antidepressant group (N = 1223) (incomplete assessment*)				
Poor	43	16 (37.2%)	-0.084 (0.892)	
Intermediate	433	153 (35.3%)	-0.118 (0.973)	
Normal	747	295 (39.5%)	-0.032 (0.991)	

Frequency with proportion for remission and mean with standard deviation for percentage improvement were displayed

<sup>\*</sup> Due to undetected variants in genotype, imputation of CYP2D6 metabolic phenotypes was less accurate

Supplementary Table 6. Meta-analyses of activity score with antidepressant outcomes

Outcomes	OR/COR	95% CI	P
CYP2C19 activity score			
Remission	0.94	0.86, 1.03	0.197
Percentage Improvement	-0.02	-0.05, 0.01	0.170

COR: correlation

Supplementary Table 7. Meta-analyses of metabolic phenotypes for percentage improvement adjusting for baseline severity of depression

j						
Metabolizers	SMD	95% CI	P			
CYP2C19						
Poor	0.13	-0.03, 0.29	0.103			
Intermediate	0.01	-0.05, 0.08	0.683			
Rapid+Ultrarapid	0.01	-0.05, 0.07	0.777			

Supplementary Table 8. Meta-analyses of CYP2C19 metabolic effect in citalopram and escitalopram

	OR/SMD	95% CI	P
Remission			
Poor	1.41	0.84, 2.34	0.192
Intermediate	0.89	0.65, 1.21	0.455
Rapid+Ultrarapid	0.99	0.83, 1.18	0.876
Percentage Improvement			
Poor	0.069	-0.16, 0.30	0.559
Intermediate	-0.004	-0.09, 0.09	0.929
Rapid+Ultrarapid	0.015	-0.07, 0.10	0.732